Mirati Therapeutics is part of the biotechnology industry and is part of the healthcare sector. The company CEO is Charles M. Baum. Mirati Therapeutics Inc is a biotechnology company. The company’s focuses on precision medicine for oncology therapeutics. The company provides bioavailable inhibitors with distinct target profiles aiming to treat cancer patients.

Previous Intraday Performance:

The MRTX shares had a previous change of 9.90% which opened at 95.59 and closed at 98.03. It moved to an intraday high of 99.37 and a low of 94.06.

SeekingAlpha:  GOGL, GTXI among premarket gainers

Historical Performance:

Over the last five trading days, MRTX shares returned 37.74% and in the past 30 trading days it returned 55.60%. Over three months, it changed 34.42%. In one year it has changed 149.76% and within that year its 52 week high was 99.37 and its 52 week low was 28.50. MRTX stock is 243.96% above its 52 week low.

Our calculations result in a 200 day moving average of 57.74 and a 50 day moving average of 69.67. Right now, MRTX stock is trading 69.77% above its 200 day moving average.

SeekingAlpha:  GOGL, GTXI among premarket gainers


The company has a market cap of $3.5b with 36.0m shares outstanding and a float of 35.8m shares. Trading volume was 2,935,326 shares and has experienced an average volume of 938,060 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is good.


The last annual reported EPS for Mirati Therapeutics was -3.18 which ended on 31st of December 2018. Based on 7 analyst estimates, the consensus EPS for the next quarter is -0.93.

Below was the last reported quarterly diluted earnings per share:

1stQtr 2019Reported 04-29-2019: -1.17
4thQtr 2018Reported 02-28-2019: -0.87
3rdQtr 2018Reported 11-06-2018: -0.85
2ndQtr 2018Reported 08-01-2018: -0.94
1stQtr 2018Reported 05-07-2018: -0.51

Base on our calculations, the intrinsic value per share is 92.37, which means it might be overvalued by -6.13%.

EPS growth is an important number as it indicates the future prospects of Mirati Therapeutics; the EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been -56.70% over the last twelve months.

Indicators Also to Watch:

The beta was calculated to be 1.78.

SeekingAlpha:  VKTX, FRSH among premarket gainers

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -55.17%, price-to-sales is 683.69 and price-to-book is 11.34.

Company Score Card:

Results are out of six:
 5  : Growth Expectations Result
 6  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here